 |
|
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
Seung-Ki Kwok
Korean J Intern Med. 2014;29(5):577-579. Published online 2014 Aug 28 DOI: https://doi.org/10.3904/kjim.2014.29.5.577
|
|
Citations to this article as recorded by
 The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
Shahin Shams, Joseph M. Martinez, John R. D. Dawson, Juan Flores, Marina Gabriel, Gustavo Garcia, Amanda Guevara, Kaitlin Murray, Noah Pacifici, Maxemiliano V. Vargas, Taylor Voelker, Johannes W. Hell, Judith F. Ashouri
Frontiers in Pharmacology.2021;[Epub] CrossRef
|